Drug Metabolism and Pharmacokinetics Core Goal: To provide comprehensive pharmacology support for preclinical and clinical research.

Slides:



Advertisements
Similar presentations
AbstractSchema Conclusion Pharmacokinetic profile of the base-excision repair inhibitor Methoxyamine-HCl (TRC102; MX) given as an one-hour intravenous.
Advertisements

Selected Clinical Calculations
Kidney Function Tests Contents: Kidney functions Functional units Renal diseases Routine kidney function tests Serum creatinine Creatinine clearance.
Pharmacokinetics as a Tool
Dosage Regimen Design in Patients with Renal Insufficiency Cont’d Pharmacy 732 Winter, 2001.
Pharmacotherapy in the Elderly Paola S. Timiras May, 2007.
Pharmacotherapy in the Elderly Judy Wong
Kidney function, two complimentary evaluations Serum and urine testing Robert L. Stout, Ph.D.
OncoTracker James Berenson, MD President and CEO November 2014.
Kidney Function Tests Rana Hasanato, MD, KSFCB
Kidney Function Tests Contents: Functional units Kidney functions Renal diseases Routine kidney function tests Serum creatinine Creatinine clearance.
LymphoStat-BTM A Case Study for Endpoints and Trial Design in SLE
Yasar Kucukardali Professor, Internal Medicine Yeditepe University.
بسم الله الرحــــــمـن الرحيم. Propionyl-L-carnitine Prevents The Progression of Cisplatin-Induced Cardiomyopathy in a Carnitine-Depleted Rat Model Mohamed.
Effect of Hepatic Impairment on Sorafenib Pharmacokinetics: Results of a Multicenter, Open-Label, Single-Dose, Phase I Trial J Lettieri, A Mazzu,
Rapivab™ - peramivir injection
Food and Drug Administration Food and Drug Administration Center for Biologics Evaluation and Research Biological Response Modifiers Advisory Committee.
A seminar on ALTERED KINETICS IN RENAL DISEASES BY A.SRILATHA (M.Pharm I sem ) Department of Pharmaceutics BLUE BIRDS COLLEGE OF PHARMACY (Affiliated to.
Pharmacokinetics (PK): What the body does to the drug? Most drugs: Enter the body by crossing barriers Distributed by the blood to the site of action Biotransform.
Dose Adjustment in Renal and Hepatic Disease
INTRAVENOUS INFUSION.
Basic & Clinical Pharmacology Influence of liver impairment in the action of sodium thiopental.
Kidney Function Tests. Kidney Function Tests Contents: Kidney functions Functional units Renal diseases Routine kidney function tests Serum creatinine.
The General Concepts of Pharmacokinetics and Pharmacodynamics Hartmut Derendorf, PhD University of Florida.
PK/PD Modeling in Support of Drug Development Alan Hartford, Ph.D. Associate Director Scientific Staff Clinical Pharmacology Statistics Merck Research.
1 I4E-MC-JXBA and JXBB Phase 2 Study to Evaluate the PK and Drug-Drug Interaction of Cetuximab and Cisplatin (JXBA) Cetuximab and Cisplatin (JXBB)
Presented by Gordon Holt, Ph.D. at the Nonclinical Studies Subcommittee of the Advisory Committee for Pharmaceutical Science March 9, 2000.
Kidney Function Tests.
From A Physiologic Perspective Chemical Clearance from the Body
FDA Case Studies Pediatric Oncology Subcommittee March 4, 2003.
Touqeer Ahmed Ph.D. Atta-ur-Rahman School of Applied Bioscience, National University of Sciences and Technology 21 st October, 2013.
INJECTAFER Pharmacokinetics (PK) and Pharmacodynamics (PD) Christy S. John, Ph.D Division of Clinical Pharmacology V Office of Clinical Pharmacology Division.
1 Adverse effect of drugs Excessive Pharmacologic Effects –overdoing the therapeutic effect –Atropine –muscarinic antagonist, desired therapeutic –Effect:
Population Pharmacokinetic Characteristics of Levosulpiride and Terbinafine in Healthy Male Korean Volunteers Yong-Bok Lee College of Pharmacy and Institute.
Drug Administration Pharmacokinetic Phase (Time course of ADME processes) Absorption Distribution Pharmaceutical Phase Disintegration of the Dosage Form.
CHEE 4401 Definitions drug - any substance that affects the structure or functioning of an organism pharmaceutics - the area of study concerned with the.
The General Concepts of Pharmacokinetics and Pharmacodynamics
CLINICAL PHARMACOKINETICS OF LIDOCAINE
Grade Statistics without Bonus with Bonus Average = 86 Median = 87 Average = 88 Median = 89 Undergraduates Average=88 MS Average=92.
Pharmacology Group I presentation
INTRODUCTION CLINICAL PHARMACOKINETICS
Renal Physiology and Function Part II Renal Function Tests
TDM Therapeutic Drug Monitoring
Pharmacokinetics of Vancomycin in Adult Oncology Patients Hadeel Al-Kofide MS.c; Iman Zaghloul PhD; and Lamya Al-Naim PharmD Department of Clinical Pharmacy,
European Patients’ Academy on Therapeutic Innovation The key principles of pharmacology.
GARLIC AND HEALTH in vivo Metabolism of DADS 4 th October 2001 Study of in vivo Diallyl disulfide Metabolism Aims of the study : –To determine the pharmacokinetic.
The General Concepts of Pharmacokinetics and Pharmacodynamics
415 PHT Plasma Level – Time Curve
г.1 PHARMACOKINETICS OF ENROFLOXACIN IN DUCKS WITH STEATOSIS AFTER FORCE-FEEDING Neno Bratoev, Lubomir Lashev Department of Pharmacology, Physiology.
RANDOMIZED PHASE II STUDY OF NABPACLITAXEL, IN RECURRENT ADVANCED OR METASTATIC CERVICAL CANCER MITO CER-NAB Enrica Mazzoni, MD Medical Oncology & Breast.
Allie punke Pharmacokinetics tutoring Fall 2016
In Vitro and In Vivo Studies of Non-Platinum-Based Halogenated Compounds as Potent Antitumor Agents for Natural Targeted Chemotherapy of Cancers  Qing-Bin.
Allie punke Pharmacokinetics tutoring Fall 2016
Drug Discovery &Development
Kidney Function Tests.
Cyclosporine.
Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-α produced by renal parenchymal cells  B. Zhang, G. Ramesh, C.C. Norbury, W.B. Reeves 
…driving discovery An improved potent direct thrombin inhibitor shows efficacy with low bleeding risk Anirban Datta et al.
Quantitative Pharmacokinetics
Pharmacokinetics.
Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator by Yan Jiao, John Wilkinson, Xiumin Di, Wei Wang,
Jinu Kim, Kelly E. Long, Kang Tang, Babu J. Padanilam 
Volume 54, Issue 5, Pages (November 1998)
Clinical Pharmacokinetics
Volume 73, Issue 11, Pages (June 2008)
The pathological role of Bax in cisplatin nephrotoxicity
Selvadurai Muralidharan, Kalaimani Jaya Raja Kumar
REFERENCE: APPLIED CLINICAL Slideshow by: lecturer HADEEL DELMAN
unbound concentration µM
Presentation transcript:

Drug Metabolism and Pharmacokinetics Core Goal: To provide comprehensive pharmacology support for preclinical and clinical research

Services: Pharmacokinetic studies: Quantify drug levels in serum/plasma, tissue or cells Evaluation of Organ Toxicity: Blood chemistry analysis for liver, kidney and bone marrow toxicity Hematology: Measure complete blood counts Measure GSH/GSSG Redox analysis: Detection of protein thiol status in cells, tissue, serum and plasma. Education and training

NOV-002, a myeloproliferative agent Phase II: Neo-adjuvant breast cancer trial at MUSC

Pharmacokinetic Analysis

B. A. ug/mL GSSG ug/mL GSH

Estimated pharmacokinetic parameters for NOV-002 (GSSG) and its primary metabolite (GSH) PK Parameter GSH GSSG C o (ug/mL) C max (ug/mL) T max (hr) Volume of distribution, V/F (L/kg) K01 (absorption rate constant), hr K10 (elimination rate constant), hr AUC 0-30min (ug.h/mL) Clearance, CL/F (L/hr/kg)

Evaluation of Organ Toxicity

Table 2. Mortality and Nephrotoxicity of Cisplatin in Mice Elevated Abnormal Mortality Creatinine Renal Histology Saline0/6*0/60/6 NOV-0020/60/60/6 Cisplatin1/8§ 6/7§7/7§ Cisplatin + NOV-0020/93/93/9 Data are the number of mice who died, had elevated plasma creatinine (>0.2 mg/dL) or abnormal renal histology over the number of mice treated. § Statistically significant differences between treatment groups were detected with a Fisher Exact Test, P<0.01.

Saline NOV-002 Cisplatin Cisplatin + NOV-002

Hematology:

Cisplatin Induced Bone Marrow Toxicity White Blood Cells HM2 Hematology System (Abaxis) Female Male x 10 9 cells/mL Normal 6 x 10 9 Female +/+ Cisplatin + + NOV

Measure GSH/GSSG Redox Potential E h (mV)

Redox analysis: -S- TG TM -SH NOV TG TM + -S-SG % Free Sulfhydryls * * * *

A B C D Kda NOV-002 (25 mg/kg, iv) 0 ¼ ½ h WB: PSSG WB: actin Identification of Plasma Markers following NOV-002 treatment

Cost Recovery System: Assay Development$1,500 + Column PK Modeling$50/ hr Plasma / Serum Assay$50 / sample Organ toxicity analysis$35 / sample Hematology (CBC)$20 / sample GSH/GSSG levels$25 / sample Protein Thiol Analysis$35 / sample Breeze HPLC –User Operated Training$ 50 / hour –User Operation fee$ 25 / hour –Over-night / weekend fee$18 / hour

Drug Metabolism and Pharmacokinetics Core Drug Discovery Building Danyelle Townsend, Ph.D., DirectorYefim Manevich, Ph.D., Drug Discovery Building Joachim Uys, Ph.D. PK project manager